Sawai Group Holdings

4887.TTSE PRIMEPharmaceutical

Financials · Consolidated

Fiscal year ended	2026-03	2025-03	2024-03	2023-03	2022-03	2021-03
Revenue	¥201.7bn	¥189.0bn	¥176.9bn	¥163.7bn^r	¥193.8bn	—
Operating income	¥15.9bn	¥4.0bn	¥18.6bn	¥16.1bn^r	−¥35.9bn	—
Net income (owners)	¥10.4bn	¥12.0bn	¥13.7bn	¥12.7bn	−¥28.3bn	—
Total assets	¥359.9bn	¥354.6bn	¥382.0bn	¥364.2bn	¥349.5bn	—
Net assets / equity	¥178.6bn	¥173.9bn	¥218.0bn	¥212.7bn	¥200.1bn	¥240.8bn
Operating cash flow	¥7.4bn	¥27.9bn	¥23.1bn	¥13.0bn	¥34.3bn	—
EPS (basic)	¥90.39	¥96.54	¥104.22^r	¥96.42^r	¥-215.18^r	—

From EDINET filings. Select any figure to open the report it came from. ^r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.

Reports · 13

All Annual 5 Half-year 2 Quarterly 62026 2025 2024 2023 2022

Period	Form	Filed	Figures
2025-04-01 → 2026-03-31	Annual	2026-06-24	213 figures · EDINET
2025-04-01 → 2025-09-30	Half-year	2025-11-14	80 figures · EDINET
2024-04-01 → 2025-03-31	Annual	2025-06-24	186 figures · EDINET
2024-04-01 → 2024-09-30	Half-year	2024-11-11	82 figures · EDINET
2023-04-01 → 2024-03-31	Annual	2024-06-25	159 figures · EDINET
2023-04-01 → 2023-12-31	Quarterly Q3	2024-02-14	106 figures · EDINET
2023-04-01 → 2023-09-30	Quarterly Q2	2023-11-10	118 figures · EDINET
2023-04-01 → 2023-06-30	Quarterly Q1	2023-08-09	88 figures · EDINET
2022-04-01 → 2023-03-31	Annual	2023-06-27	135 figures · EDINET
2022-04-01 → 2022-12-31	Quarterly Q3	2023-02-13	118 figures · EDINET
2022-04-01 → 2022-09-30	Quarterly Q2	2022-11-08	118 figures · EDINET
2022-04-01 → 2022-06-30	Quarterly Q1	2022-08-10	88 figures · EDINET
2021-04-01 → 2022-03-31	Annual	2022-06-24	68 figures · EDINET

3 more reports are still being processed.

Segments · FY ended 2023-03

Segment	External sales	Profit
Japan	¥163.7bn	¥16.1bn
USA	¥36.6bn	¥930m
Adjustments & eliminations	—	¥0
Total	¥200.3bn	¥17.0bn

Segment names from EDINET member IDs; not mapped to a common taxonomy.